Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: Impact of age and renal function on area under the curve

Journal of Cancer Research and Clinical Oncology

Volumn 127, Issue 1, 2001, Pages 64-68

  Kern, W ^a   Braess, J ^a   Friedrichsen, S ^a   Kaufmann, C C ^a   Schleyer, E ^b   Hiddemann, W ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Age; Carboplatin; Creatinine clearance; Pharmacokinetics

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG DERIVATIVE; TAXOID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; KIDNEY FUNCTION; LUNG CANCER; PRIORITY JOURNAL; ADULT; AGE; AGED; AREA UNDER THE CURVE; ATOMIC ABSORPTION SPECTROMETRY; FEMALE; KIDNEY; KINETICS; LUNG TUMOR; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TIME; ADVANCED CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG URINE LEVEL;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CARBOPLATIN; FEMALE; HUMANS; KIDNEY; KINETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; REGRESSION ANALYSIS; SPECTROPHOTOMETRY, ATOMIC; TAXOIDS; TIME FACTORS;

EID: 0034744328     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320000169     Document Type: Article

References (43)

1. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing
2. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
3. A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide
4. How to predict carboplatin clearance from standard morphological and biological characteristics in obese patients
5. Cisplatin pharmacokinetics in elderly patients
6. Glomerular filtration rate measurement: A neglected test in urological practice
7. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
8. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
9. Prediction of carboplatin clearance from standard morphological and biological patient characteristics
10. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
11. A comparison between estimates of GFR using [99mTc]DTPA clearance and the approximation of Cockcroft and Gault
12. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240)
13. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose
14. Clinical value of the creatinine clearance before the administration of chemotherapy with cisplatin
15. Evaluation of two dose individualisation methods for carboplatin
16. A sequential Bayesian algorithm for dose individualisation of carboplatin
17. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum
18. Pharmacokinetics of carboplatin after i.v. administration
19. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h
20. Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function
21. Model building in pharmacokinetics/Part III: Simplified rules for the deduction of analytical solutions for linear compartment models
22. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial
23. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer
24. Pharmacokinetics of cisplatin and its impact on nephrotoxicity during intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer
25. Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: Impact of age and renal function on area under the curve
26. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
27. Chemotherapy of advanced ovarian cancer
28. Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided Over three consecutive days
29. Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula
30. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma
31. A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin
32. Clinical pharmacokinetics of carboplatin in children
33. Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate
34. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support
35. Platinum analogue combination chemotherapy: Cisplatin and carboplatin-a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion
36. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans
37. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin
38. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support
39. Advanced ovarian cancer. Carboplatin versus cisplatin
40. The accuracy of creatinine clearance with and without urine collection as a measure of glomerular filtration rate
41. New cisplatin analogues in development. A review
42. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: Correlation of plasma drug levels with renal toxicity
43. The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function